AMRX
NASDAQ · Pharmaceuticals
Amneal Pharmaceuticals Inc
$19.45
-0.50 (-2.51%)
Financial Highlights (FY 2026)
Revenue
3.33B
Net Income
79.44M
Gross Margin
36.9%
Profit Margin
2.4%
Rev Growth
+10.9%
D/E Ratio
136.58
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 36.9% | 36.9% | 31.8% | 31.8% |
| Operating Margin | 13.0% | 11.7% | 35.6% | 35.2% |
| Profit Margin | 2.4% | 2.3% | 34.4% | 33.5% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 3.33B | 3.00B | 607.96M | 566.33M |
| Gross Profit | 1.23B | 1.11B | 193.42M | 180.17M |
| Operating Income | 434.39M | 352.46M | 216.47M | 199.53M |
| Net Income | 79.44M | 64.46M | 209.30M | 189.93M |
| Gross Margin | 36.9% | 36.9% | 31.8% | 31.8% |
| Operating Margin | 13.0% | 11.7% | 35.6% | 35.2% |
| Profit Margin | 2.4% | 2.3% | 34.4% | 33.5% |
| Rev Growth | +10.9% | +10.9% | -4.4% | -5.2% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 3.41B | 3.41B | 254.87M | 263.92M |
| Total Equity | 24.97M | 24.97M | 2.84B | 2.75B |
| D/E Ratio | 136.58 | 136.58 | 0.09 | 0.10 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 681.09M | 583.34M | 317.16M | 296.42M |
| Free Cash Flow | — | — | 187.04M | 181.02M |